Clinical Trial

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-27; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-06-10
Trial Details
NCT Number NCT07006077
Lead Sponsor Hangzhou Converd Co., Ltd.
Conditions Advanced Pancreatic Cancer
Enrollment 12 participants
Start Date 2025-05-29
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-03-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-27